Read + Share
Nierengarten MB. ASCO 2024: Advances in lung cancer treatments and care: A new standard of care
therapy based on the results of the LAURA study underscores the need for testing
for epidermal growth factor receptor (EGFR) mutations in patients with
unresectable stage I Cancer 2024;130:2894.
PMID: 39117502
|
 |
|
